TTR and amyloidosis: Tafamidis is an exception since it has been used with great success in several countries in recent years to treat patients with familial amyloid polyneuropathy, a transthyretin (TTR)-related amyloidosis (Coelho et al., 2012), and more recently, familial cardiomyopathy (Maurer et al., 2018).